3SBIO (01530) surged nearly 5% again, reaching HK$35.14 by the time of writing, with a trading volume of HK$1.129 billion. The company presented Phase 2 clinical trial data for its 707 combination therapy in treating 1LNSCLC at the 2025 STIC conference.

Meanwhile, Pfizer announced its global clinical strategy for 707, accelerating development after partnering with 3SBIO. The drug has been designated as a core pipeline asset, with five new clinical applications submitted. Pfizer's second-wave development plan aims to initiate trials for 10 additional indications and over 10 novel combination therapies by late 2026.

Huatai Securities noted that on October 30, Pfizer registered two global Phase 3 trials (NSCLC and CRC) for PF-08634404 (SSGJ-707) on Clinicaltrials.gov, marking the official launch of overseas clinical studies. The firm believes Pfizer's rapid progress with 707 surpasses market expectations, reflecting FDA recognition of China's innovative drugs. Further catalysts, including ADC combination trials, could drive sustained valuation growth for 3SBIO.